Mesenchymal stem cell treatment for COVID-19

Area of Science:

• Immunology
• Regenerative Medicine
• Infectious Diseases

Background:

• Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection caused a global pandemic with over 360 million cases.
• A small percentage of infected individuals develop severe or critical illness, necessitating novel therapeutic strategies.
• Despite vaccination efforts, reinfections and breakthrough cases persist, highlighting the need for advanced treatments.

Purpose of the Study:

• To review the pathological characteristics of COVID-19.
• To provide evidence for the safety and efficacy of Mesenchymal stem cells (MSCs) in treating COVID-19.
• To explore MSCs as an immunotherapy option for reducing lung pathology.

Main Methods:

• Literature review of COVID-19 pathology.
• Analysis of preclinical and clinical studies on MSC therapy for COVID-19.
• Summary of registered clinical trials involving MSCs and COVID-19.

Main Results:

• Over 80 clinical trials registered for Mesenchymal stem cells (MSCs) and COVID-19 as of January 16, 2022.
• Preclinical and clinical studies suggest MSC therapy is safe.
• Evidence indicates potential effectiveness of MSCs in managing COVID-19.

Conclusions:

• Mesenchymal stem cells (MSCs) possess immunomodulatory, anti-inflammatory, and regenerative properties beneficial for COVID-19 treatment.
• MSC therapy presents a safe and potentially effective immunotherapeutic approach for severe COVID-19.
• Further research and clinical application of MSCs are warranted for managing SARS-CoV-2-induced lung injury.